USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells
Summary
The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.
What changed
This document is a USPTO patent application (US20260083729A1) filed by Imago Biosciences, Inc. on December 15, 2023. It describes methods for increasing hematopoietic stem cells (HSCs) and treating conditions like bone marrow failure (BMF) by administering an LSD1 inhibitor. The application also covers enhancing recovery from cancer therapy and accelerating hematopoietic compartment recovery after physical insult.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in therapeutic approaches for blood disorders and cancer treatment recovery. Companies in the pharmaceutical and biotechnology sectors involved in HSC research or BMF therapies should be aware of this filing as it may indicate emerging intellectual property and competitive landscapes.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TREATMENT OF BONE MARROW FAILURE AND RELATED CONDITIONS
Application US20260083729A1 Kind: A1 Mar 26, 2026
Assignee
Imago Biosciences, Inc.
Inventors
Maria Kleppe, Hugh Y. Rienhoff, JR., Jennifer Dias
Abstract
Provided herein are methods for increasing the numbers of hematopoietic stem cells (HSCs) in a patient in need thereof, for treating a condition characterized by reduced numbers of hematopoietic stem cells (HSCs), such as bone marrow failure (BMF) or a BMF syndrome, in a patient in need thereof, for enhancing recovery from or improving tolerance of a near-ablative cancer therapy, and/or for reducing the damage to, or accelerating the recovery of, the hematopoietic compartment after a physical insult thereto in a patient in need thereof, comprising administering in vivo or treating cells ex vivo with an LSD1 inhibitor.
CPC Classifications
A61K 31/496 A61K 35/12 A61P 7/00 A61K 2035/124
Filing Date
2023-12-15
Application No.
19137870
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.